Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

Hongjuan Zhang; Cheng Zhan; Ji Ke; Zhiqiang Xue; Aiqun Zhang; Kaifeng Xu; Zhirong Shen; Lei Yu; Liang Chen

doi:10.18632/oncotarget.26255

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

PDF | How to cite

Oncotarget. 2018; 9:35285-35285. https://doi.org/10.18632/oncotarget.26255

Metrics: PDF 1404 views | ?

Hongjuan Zhang^1,2, Cheng Zhan², Ji Ke³, Zhiqiang Xue⁴, Aiqun Zhang⁴, Kaifeng Xu⁵, Zhirong Shen^2,6, Lei Yu³ and Liang Chen^2,7

¹ School of Life Science, Tsinghua University, Beijing 100084, China
² National Institute of Biological Sciences, Beijing 102206, China
³ Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
⁴ The General Hospital of People’s Liberation Army (301 Hospital), Beijing 100853, China
⁵ Peking Union Medical College Hospital, Beijing 100730, China
⁶ Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China
⁷ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, 102206, China

Published: October 16, 2018

This article has been corrected: The correct Acknowledgment information is given below:

ACKNOWLEDGMENT

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2016; 7:3367-3378. DOI: https://doi.org/10.18632/oncotarget.6491.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26255

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment